Compare AZZ & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AZZ | IRON |
|---|---|---|
| Founded | 1956 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 3.4B |
| IPO Year | N/A | N/A |
| Metric | AZZ | IRON |
|---|---|---|
| Price | $107.02 | $79.40 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 13 |
| Target Price | ★ $116.33 | $108.85 |
| AVG Volume (30 Days) | 193.3K | ★ 756.6K |
| Earning Date | 01-07-2026 | 11-06-2025 |
| Dividend Yield | ★ 0.74% | N/A |
| EPS Growth | ★ 855.67 | N/A |
| EPS | ★ 10.37 | N/A |
| Revenue | ★ $1,594,766,000.00 | N/A |
| Revenue This Year | $5.21 | N/A |
| Revenue Next Year | $5.18 | N/A |
| P/E Ratio | $10.40 | ★ N/A |
| Revenue Growth | ★ 1.55 | N/A |
| 52 Week Low | $70.90 | $30.82 |
| 52 Week High | $119.95 | $99.50 |
| Indicator | AZZ | IRON |
|---|---|---|
| Relative Strength Index (RSI) | 55.82 | 34.31 |
| Support Level | $106.66 | $86.75 |
| Resistance Level | $110.31 | $94.51 |
| Average True Range (ATR) | 2.78 | 4.95 |
| MACD | 0.09 | -1.40 |
| Stochastic Oscillator | 50.76 | 33.35 |
AZZ Inc is a provider of galvanizing and a variety of metal coating solutions and coil coating solutions to a broad range of end markets in North America. The company's operating segment consists of Metal Coatings, Precoat Metals, and Infrastructure Solutions. The company generates the majority of its revenue from the Precoat Metals segment, which provides coil coating application of protective and decorative coatings and related value-added downstream processing for steel and aluminum coils. Geographically, the company generates the majority of its revenue from the United States.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.